CD8 T-cell-mediated protection against liver-stage malaria: Lessons from a mouse model

Frontiers in Microbiology

Volumn 5, Issue JUN, 2014, Pages

  Van Braeckel Budimir, Natalija ^a   Harty, John T ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

CD8 T cells; Humans; Memory; Mice; Plasmodium; Protection

Indexed keywords

CD11 ANTIGEN; CD8ALPHA ANTIGEN; CIRCUMSPOROZOITE PROTEIN; EPITOPE; FAS LIGAND; GAMMA INTERFERON; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; PERFORIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VACCINE;

ANIMAL MODEL; ANTIGEN SPECIFICITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROTECTION; CELLULAR IMMUNITY; CONCURRENT INFECTION; DENDRITIC CELL; DISEASE COURSE; DISEASE MODEL; DRUG ADMINISTRATION ROUTE; GENETIC MANIPULATION; HOST PARASITE INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; LIVER CELL; LIVER STAGE PLASMODIUM INFECTION; MALARIA; MEMORY T LYMPHOCYTE; MEROZOITE; MOSQUITO BITE; MOUSE; NONHUMAN; ONCOGENE RAS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMODIUM BERGHEI; PLASMODIUM YOELII; REVIEW; SPOROZOITE; STERILIZING IMMUNITY; VACCINATION;

EID: 84905189821     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2014.00272     Document Type: Review

References (75)

1. Agnandji, S. T., Lell, B., Fernandes, J. F., Abossolo, B. P., Methogo, B. G., Kabwende, A. L., et al. (2012). A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367, 2284-2295. doi: 10.1056/NEJMoa1208394
2. Aly, A. S., Mikolajczak, S. A., Rivera, H. S., Camargo, N., Jacobs-Lorena, V., Labaied, M., et al. (2008). Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver infection. Mol. Microbiol. 69, 152-163. doi: 10.1111/j.1365-2958.2008.06271.x
3. Badovinac, V. P., Messingham, K. A., Jabbari, A., Haring, J. S., and Harty, J. T. (2005). Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination. Nat. Med. 11, 748-756. doi: 10.1038/nm1257
4. Baer, K., Klotz, C., Kappe, S. H., Schnieder, T., and Frevert, U. (2007). Release of hepatic Plasmodium yoelii merozoites into the pulmonary microvasculature. PLoS Pathog. 3:e171. doi: 10.1371/journal.ppat.0030171
5. Bejon, P., Mwacharo, J., Kai, O., Mwangi, T., Milligan, P., Todryk, S., et al. (2006). A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin. Trials 1:e29. doi: 10.1371/journal.pctr.0010029
6. Bejon, P., Ogada, E., Mwangi, T., Milligan, P., Lang, T., Fegan, G., et al. (2007). Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS ONE 2:e707. doi: 10.1371/journal.pone.0000707
7. Butler, N. S., Schmidt, N. W., and Harty, J. T. (2010). Differential effector pathways regulate memory CD8 T cell immunity against Plasmodium berghei versus P. yoelii sporozoites. J. Immunol. 184, 2528-2538. doi: 10.4049/jimmunol.0903529
8. Butler, N. S., Schmidt, N. W., Vaughan, A. M., Aly, A. S., Kappe, S. H., and Harty, J. T. (2011). Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe 9, 451-462. doi: 10.1016/j.chom.2011.05.008
9. Chattopadhyay, R., Conteh, S., Li, M., James, E. R., Epstein, J. E., and Hoffman, S. L. (2009). The effects of radiation on the safety and protective efficacy of an attenuated Plasmodium yoelii sporozoite malaria vaccine. Vaccine 27, 3675-3680. doi: 10.1016/j.vaccine.2008.11.073
10. Clyde, D. F., Most, H., Mccarthy, V. C., and Vanderberg, J. P. (1973). Immunization of man against sporozite-induced falciparum malaria. Am. J. Med. Sci. 266, 169-177. doi: 10.1097/00000441-197309000-00002
11. Colloca, S., Barnes, E., Folgori, A., Ammendola, V., Capone, S., Cirillo, A., et al. (2012). Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci. Transl. Med. 4, 115ra112. doi: 10.1126/scitranslmed.3002925
12. Corbett, E. L., Marston, B., Churchyard, G. J., and De Cock, K. M. (2006). Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 367, 926-937. doi: 10.1016/S0140-6736(06)68383-9
13. Diosi, P. (2002). Genetic control of innate immune responses against cytomegalovirus: MCMV meets its match. Genes Immun. 3, 501. doi: 10.1038/sj.gene.6363938
14. Doolan, D. L., and Hoffman, S. L. (1999). IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model. J. Immunol. 163, 884-892.
15. Doolan, D. L., and Hoffman, S. L. (2000). The complexity of protective immunity against liver-stage malaria. J. Immunol. 165, 1453-1462. doi: 10.4049/jimmunol.165.3.1453
16. Dunachie, S. J., Walther, M., Epstein, J. E., Keating, S., Berthoud, T., Andrews, L., et al. (2006). A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect. Immun. 74, 5933-5942. doi: 10.1128/IAI.00590-06
17. Edelman, R., Hoffman, S. L., Davis, J. R., Beier, M., Sztein, M. B., Losonsky, G., et al. (1993). Long-term persistence of sterile immunity in a volunteer immunized with X-irradiated Plasmodium falciparum sporozoites. J. Infect. Dis. 168, 1066-1070. doi: 10.1093/infdis/168.4.1066
18. Epstein, J. E., Tewari, K., Lyke, K. E., Sim, B. K., Billingsley, P. F., Laurens, M. B., et al. (2011). Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Science 334, 475-480. doi: 10.1126/science.1211548
19. Ewer, K. J., O'hara, G. A., Duncan, C. J., Collins, K. A., Sheehy, S. H., Reyes-Sandoval, A., et al. (2013). Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat. Commun. 4, 2836. doi: 10.1038/ncomms3836
20. Ferreira, A., Schofield, L., Enea, V., Schellekens, H., Van Der Meide, P., Collins, W. E., et al. (1986). Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon. Science 232, 881-884. doi: 10.1126/science.3085218
21. Hill, A. V., Reyes-Sandoval, A., O'Hara, G., Ewer, K., Lawrie, A., Goodman, A., et al. (2010). Prime-boost vectored malaria vaccines: progress and prospects. Hum. Vaccin. 6, 78-83. doi: 10.4161/hv.6.1.10116
22. Hoffman, S. L., Goh, L. M., Luke, T. C., Schneider, I., Le, T. P., Doolan, D. L., et al. (2002). Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J. Infect. Dis. 185, 1155-1164. doi: 10.1086/339409
23. Hotez, P. J., and Kamath, A. (2009). Neglected tropical diseases in sub-saharan Africa: review of their prevalence, distribution, and disease burden. PLoS Negl. Trop. Dis. 3:e412. doi: 10.1371/journal.pntd.0000412
24. Hsieh, C. S., Macatonia, S. E., O'garra, A., and Murphy, K. M. (1995). T cell genetic background determines default T helper phenotype development in vitro. J. Exp. Med. 181, 713-721. doi: 10.1084/jem.181.2.713
25. Ishikawa, T., Yamada, H., Oyamada, A., Goshima, F., Nishiyama, Y., and Yoshikai, Y. (2009). Protective role of Fas-FasL signaling in lethal infection with herpes simplex virus type 2 in mice. J. Virol. 83, 11777-11783. doi: 10.1128/JVI.01006-09
26. Jobe, O., Lumsden, J., Mueller, A. K., Williams, J., Silva-Rivera, H., Kappe, S. H., et al. (2007). Genetically attenuated Plasmodium berghei liver stages induce sterile protracted protection that is mediated by major histocompatibility complex Class I-dependent interferon-gamma-producing CD8+ T cells. J. Infect. Dis. 196, 599-607. doi: 10.1086/519743
27. Kappe, S. H., Vaughan, A. M., Boddey, J. A., and Cowman, A. F. (2010). That was then but this is now: malaria research in the time of an eradication agenda. Science 328, 862-866. doi: 10.1126/science.1184785
28. Labaied, M., Harupa, A., Dumpit, R. F., Coppens, I., Mikolajczak, S. A., and Kappe, S. H. (2007). Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection. Infect. Immun. 75, 3758-3768. doi: 10.1128/IAI.00225-07
29. Lanar, D. E., Tine, J. A., De Taisne, C., Seguin, M. C., Cox, W. I., Winslow, J. P., et al. (1996). Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria. Infect. Immun. 64, 1666-1671.
30. Magambo, J., Njoroge, E., and Zeyhle, E. (2006). Epidemiology and control of echinococcosis in sub-Saharan Africa. Parasitol. Int. 55(Suppl.) S193-S195. doi: 10.1016/j.parint.2005.11.029
31. Meis, J. F., Verhave, J. P., Jap, P. H., Sinden, R. E., and Meuwissen, J. H. (1983). Malaria parasites - discovery of the early liver form. Nature 302, 424-426. doi: 10.1038/302424a0
32. Menard, R., Tavares, J., Cockburn, I., Markus, M., Zavala, F., and Amino, R. (2013). Looking under the skin: the first steps in malarial infection and immunity. Nat. Rev. Microbiol. 11, 701-712. doi: 10.1038/nrmicro3111
33. Miller, L. H., Ackerman, H. C., Su, X. Z., and Wellems, T. E. (2013). Malaria biology and disease pathogenesis: insights for new treatments. Nat. Med. 19, 156-167. doi: 10.1038/nm.3073
34. Moorthy, V. S., and Ballou, W. R. (2009). Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malar. J. 8, 312. doi: 10.1186/1475-2875-8-312
35. Moorthy, V. S., Imoukhuede, E. B., Milligan, P., Bojang, K., Keating, S., Kaye, P., et al. (2004). A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med. 1:e33. doi: 10.1371/journal.pmed.0010033
36. Mueller, A. K., Camargo, N., Kaiser, K., Andorfer, C., Frevert, U., Matuschewski, K., et al. (2005a). Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface. Proc. Natl. Acad. Sci. U.S.A. 102, 3022-3027. doi: 10.1073/pnas.0408442102
37. Mueller, A. K., Labaied, M., Kappe, S. H., and Matuschewski, K. (2005b). Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433, 164-167. doi: 10.1038/nature03188
38. Nussenzweig, R. S., Vanderberg, J., Most, H., and Orton, C. (1967). Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium berghei. Nature 216, 160-162. doi: 10.1038/216160a0
39. Nussenzweig, R. S., Vanderberg, J. P., Most, H., and Orton, C. (1969). Specificity of protective immunity produced by x-irradiated Plasmodium berghei sporozoites. Nature 222, 488-489. doi: 10.1038/222488a0
40. Ockenhouse, C. F., Sun, P. F., Lanar, D. E., Wellde, B. T., Hall, B. T., Kester, K., et al. (1998). Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J. Infect. Dis. 177, 1664-1673. doi: 10.1086/515331
41. O'Hara, G. A., Duncan, C. J., Ewer, K. J., Collins, K. A., Elias, S. C., Halstead, F. D., et al. (2012). Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J. Infect. Dis. 205, 772-781. doi: 10.1093/infdis/jir850
42. Potocnjak, P., Yoshida, N., Nussenzweig, R. S., and Nussenzweig, V. (1980). Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J. Exp. Med. 151, 1504-1513. doi: 10.1084/jem.151.6.1504
43. Raeder, R. H., Barker-Merrill, L., Lester, T., Boyle, M. D., and Metzger, D. W. (2000). A pivotal role for interferon-gamma in protection against group A streptococcal skin infection. J. Infect. Dis. 181, 639-645. doi: 10.1086/315281
44. Rai, D., Pham, N. L., Harty, J. T., and Badovinac, V. P. (2009). Tracking the total CD8 T cell response to infection reveals substantial discordance in magnitude and kinetics between inbred and outbred hosts. J. Immunol. 183, 7672-7681. doi: 10.4049/jimmunol.0902874
45. Renggli, J., Hahne, M., Matile, H., Betschart, B., Tschopp, J., and Corradin, G. (1997). Elimination of P. berghei liver stages is independent of Fas (CD95/Apo-I) or perforin-mediated cytotoxicity. Parasite Immunol. 19, 145-148. doi: 10.1046/j.1365-3024.1997.d01-190.x
46. Rodrigues, E. G., Claassen, J., Lee, S., Wilson, J. M., Nussenzweig, R. S., and Tsuji, M. (2000). Interferon-gamma-independent CD8+ T cell-mediated protective anti-malaria immunity elicited by recombinant adenovirus. Parasite Immunol. 22, 157-160. doi: 10.1046/j.1365-3024.2000.00289.x
47. Rodrigues, E. G., Zavala, F., Eichinger, D., Wilson, J. M., and Tsuji, M. (1997). Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria. J. Immunol. 158, 1268-1274.
48. Rodrigues, M. M., Cordey, A. S., Arreaza, G., Corradin, G., Romero, P., Maryanski, J. L., et al. (1991). CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. Int. Immunol. 3, 579-585. doi: 10.1093/intimm/3.6.579
49. Roestenberg, M., Teirlinck, A. C., Mccall, M. B. B., Teelen, K., Makamdop, K. N., Wiersma, J., et al. (2011). Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 377, 1770-1776. doi: 10.1016/S0140-6736(11)60360-7
50. Sadoff, J. C., Ballou, W. R., Baron, L. S., Majarian, W. R., Brey, R. N., Hockmeyer, W. T., et al. (1988). Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science 240, 336-338. doi: 10.1126/science.3281260
51. Schmidt, N. W., Butler, N. S., Badovinac, V. P., and Harty, J. T. (2010). Extreme CD8 T cell requirements for anti-malarial liver-stage immunity following immunization with radiation attenuated sporozoites. PLoS Pathog. 6:e1000998. doi: 10.1371/journal.ppat.1000998
52. Schmidt, N. W., Butler, N. S., and Harty, J. T. (2009). CD8 T cell immunity to Plasmodium permits generation of protective antibodies after repeated sporozoite challenge. Vaccine 27, 6103-6106. doi: 10.1016/j.vaccine.2009.08.025
53. Schmidt, N. W., Butler, N. S., and Harty, J. T. (2011). Plasmodium-host interactions directly influence the threshold of memory CD8 T cells required for protective immunity. J. Immunol. 186, 5873-5884. doi: 10.4049/jimmunol.1100194
54. Schmidt, N. W., and Harty, J. T. (2011). Cutting edge: attrition of Plasmodium-specific memory CD8 T cells results in decreased protection that is rescued by booster immunization. J. Immunol. 186, 3836-3840. doi: 10.4049/jimmunol.1003949
55. Schmidt, N. W., Podyminogin, R. L., Butler, N. S., Badovinac, V. P., Tucker, B. J., Bahjat, K. S., et al. (2008). Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. Proc. Natl. Acad. Sci. U.S.A. 105, 14017-14022. doi: 10.1073/pnas.0805452105
56. Schofield, L., Villaquiran, J., Ferreira, A., Schellekens, H., Nussenzweig, R., and Nussenzweig, V. (1987). Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 330, 664-666. doi: 10.1038/330664a0
57. Sedegah, M., Weiss, W. W., and Hoffman, S. L. (2007). Cross-protection between attenuated Plasmodium berghei and P. yoelii sporozoites. Parasite Immunol. 29, 559-565. doi: 10.1111/j.1365-3024.2007.00976.x
58. Seder, R. A., Chang, L. J., Enama, M. E., Zephir, K. L., Sarwar, U. N., Gordon, I. J., et al. (2013). Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341, 1359-1365. doi: 10.1126/science.1241800
59. Selin, L. K., Lin, M. Y., Kraemer, K. A., Pardoll, D. M., Schneck, J. P., Varga, S. M., et al. (1999). Attrition of T cell memory: selective loss of LCMV epitope-specific memory CD8 T cells following infections with heterologous viruses. Immunity 11, 733-742. doi: 10.1016/S1074-7613(00)80147-8
60. Selin, L. K., Vergilis, K., Welsh, R. M., and Nahill, S. R. (1996). Reduction of otherwise remarkably stable virus-specific cytotoxic T lymphocyte memory by heterologous viral infections. J. Exp. Med. 183, 2489-2499. doi: 10.1084/jem.183.6.2489
61. Shrestha, B., Wang, T., Samuel, M. A., Whitby, K., Craft, J., Fikrig, E., et al. (2006). Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection. J. Virol. 80, 5338-5348. doi: 10.1128/JVI.00274-06
62. Shrestha, B., Zhang, B., Purtha, W. E., Klein, R. S., and Diamond, M. S. (2008). Tumor necrosis factor alpha protects against lethal West Nile virus infection by promoting trafficking of mononuclear leukocytes into the central nervous system. J. Virol. 82, 8956-8964. doi: 10.1128/JVI.01118-08
63. Sturm, A., Amino, R., Van De Sand, C., Regen, T., Retzlaff, S., Rennenberg, A., et al. (2006). Manipulation of host hepatocytes by the malaria parasite for delivery into liver sinusoids. Science 313, 1287-1290. doi: 10.1126/science.1129720
64. Sturm, A., and Heussler, V. (2007). Live and let die: manipulation of host hepatocytes by exoerythrocytic Plasmodium parasites. Med. Microbiol. Immunol. 196, 127-133. doi: 10.1007/s00430-007-0044-3
65. Tarun, A. S., Dumpit, R. F., Camargo, N., Labaied, M., Liu, P., Takagi, A., et al. (2007). Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells. J. Infect. Dis. 196, 608-616. doi: 10.1086/519742
66. Tarun, A. S., Peng, X., Dumpit, R. F., Ogata, Y., Silva-Rivera, H., Camargo, N., et al. (2008). A combined transcriptome and proteome survey of malaria parasite liver stages. Proc. Natl. Acad. Sci. U.S.A. 105, 305-310. doi: 10.1073/pnas.0710780104
67. Todryk, S. M., and Hill, A. V. (2007). Malaria vaccines: the stage we are at. Nat. Rev. Microbiol. 5, 487-489. doi: 10.1038/nrmicro1712
68. Trapani, J. A., and Smyth, M. J. (2002). Functional significance of the perforin/granzyme cell death pathway. Nat. Rev. Immunol. 2, 735-747. doi: 10.1038/nri911
69. Tsuji, M., Miyahira, Y., Nussenzweig, R. S., Aguet, M., Reichel, M., and Zavala, F. (1995). Development of antimalaria immunity in mice lacking IFN-gamma receptor. J. Immunol. 154, 5338-5344.
70. Weiss, W. R., Good, M. F., Hollingdale, M. R., Miller, L. H., and Berzofsky, J. A. (1989). Genetic control of immunity to Plasmodium yoelii sporozoites. J. Immunol. 143, 4263-4266.
71. Weiss, W. R., Sedegah, M., Beaudoin, R. L., Miller, L. H., and Good, M. F. (1988). CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc. Natl. Acad. Sci. U.S.A. 85, 573-576. doi: 10.1073/pnas.85.2.573
72. Weiss, W. R., Sedegah, M., Berzofsky, J. A., and Hoffman, S. L. (1993). The role of CD4+ T cells in immunity to malaria sporozoites. J. Immunol. 151, 2690-2698.
73. Welsh, R. M., and Selin, L. K. (2009). Attrition of memory CD8 T cells. Nature 459, E3-E4; discussion E4. doi: 10.1038/nature08091
74. WHO. (2011). World Malaria Report 2011. Geneva: World Health Organization, Available at: http://www.who.int/malaria/world_malaria_report_2011
75. Yoshida, N., Nussenzweig, R. S., Potocnjak, P., Nussenzweig, V., and Aikawa, M. (1980). Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science 207, 71-73. doi: 10.1126/science.6985745